Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback
The U.S. FDA rejection of an MDMA-based drug from Lykos Therapeutics for PTSD in August 2024 has not dimmed hopes that other psychedelic-oriented therapies can gain approval, according to the CEO of ...
manilatimes4d
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient's continued service with the Company through the ...